Swarna Varma, MD
Endocrinology, Diabetes & Metabolism · Pittsburgh, PANPI 1073599445
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $422,820 of the $520,355 with a category attached, or 81.3%. Lilly USA, LLC accounts for 68.3% of it on its own, with 38 other manufacturers making up the rest. Reporting peaked in 2019 at $189,532 and has fallen 64.9% since, to $66,618 in 2025. Among endocrinology, diabetes & metabolism clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,543 payments — averaging $337.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$355K
- Amarin Pharma, Inc.$49K
- AstraZeneca$29K
- Sanofi-aventis U.S. LLC$24K
- Bayer$23K
- Merck$13K
- plus $28K from 33 others
What the payments were for
- Consulting fees$5,4751%
- Speaking & faculty fees$422,82081%
- Travel & lodging$74,87614%
- Food & beverage$17,1403%
- Education$440%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 772 | $355,258 |
| Amarin Pharma, Inc. | 93 | $49,105 |
| AstraZeneca(2 entities) | 101 | $28,846 |
| Sanofi-aventis U.S. LLC | 88 | $23,566 |
| Bayer | 65 | $23,226 |
| Merck | 58 | $12,752 |
| AbbVie | 69 | $9,969 |
| Esperion Therapeutics, Inc. | 14 | $5,741 |
| Abbott | 25 | $3,822 |
| Medtronic(2 entities) | 48 | $2,477 |
| Tandem Diabetes Care, Inc. | 3 | $1,796 |
| Amneal Pharmaceuticals LLC | 53 | $1,476 |
| BD | 20 | $374 |
| Novo Nordisk | 32 | $331 |
| Dexcom, Inc. | 25 | $310 |
| Amgen | 12 | $181 |
| Kowa Pharmaceuticals America, Inc. | 14 | $173 |
| Xeris Pharmaceuticals, Inc. | 6 | $97 |
| Sanofi | 1 | $90 |
| Embecta Corp. | 5 | $85 |
| Ascendis Pharma Endocrinology Inc | 4 | $78 |
| Corcept Therapeutics | 4 | $71 |
| Boehringer Ingelheim | 4 | $69 |
| Insulet Corporation | 3 | $52 |
| Neurocrine Biosciences, Inc. | 2 | $51 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $46 |
| Pfizer | 2 | $40 |
| BETA Bionics, Inc. | 2 | $34 |
| Madrigal Pharmaceuticals | 1 | $32 |
| IBSA Pharma Inc. | 2 | $31 |
| Zealand Pharma US, Inc. | 2 | $31 |
| Amphastar Pharmaceuticals, Inc. | 2 | $30 |
| Novartis | 1 | $20 |
| Sequel Med Tech, LLC | 1 | $17 |
| Ultragenyx Pharmaceutical Inc. | 1 | $17 |
| Antares Pharma, Inc. | 1 | $17 |
| GRT US Holding, Inc. | 1 | $16 |
| Shield Therapeutics Inc | 1 | $15 |
| Lifescan, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$142,941
- TRULICITY$118,172
- Vascepa$47,295
- BAQSIMI$33,946
- FARXIGA$27,135
- Kerendia$22,383
- SOLIQUA 100/33$14,413
- STEGLATRO$12,300
- TOUJEO$8,362
- Synthroid$6,970
- NEXLIZET$5,452
- NEXLETOL$5,452
- FreeStyle Libre Pro$3,452
- t:slim X2 Insulin Pump with Control-IQ$1,712
- Minimed 670G System$1,139
- MINIMED 780G$587
- UNITHROID$500
How this compares
$520,355 in reported general payments places this provider in the 95th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.
See all endocrinology, diabetes & metabolism providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 1,268 | $1,546,298 |
| OzempicSemaglutide | 231 | $287,411 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 324 | $206,275 |
| FarxigaDapagliflozin Propanediol | 176 | $153,584 |
| TrulicityDulaglutide | 106 | $140,322 |
| VascepaIcosapent Ethyl | 217 | $139,784 |
| TradjentaLinagliptin | 115 | $101,327 |
| Icosapent Ethyl | 270 | $89,995 |
| JardianceEmpagliflozin | 97 | $85,443 |
| KerendiaFinerenone | 71 | $70,668 |
| Humalog Kwikpen U-100Insulin Lispro | 226 | $62,478 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 76 | $49,821 |
| Repaglinide | 946 | $47,139 |
| SynthroidLevothyroxine Sodium | 495 | $47,063 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 30 | $41,983 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $355,258 | $1,686,6201,374 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $331 | $305,051257 claims |
| Boehringer IngelheimTradjenta, Jardiance, Synjardy | $69 | $199,396226 claims |
| AstraZenecaFarxiga | $28,846 | $153,584176 claims |
| BayerKerendia | $23,226 | $70,66871 claims |
| AbbVieSynthroid | $9,969 | $47,063495 claims |
| MerckJanuvia | $12,752 | $27,89121 claims |
| Amneal Pharmaceuticals LLCUnithroid | $1,476 | $9,083385 claims |
| PfizerLevoxyl | $40 | $7,564223 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.
Other endocrinology, diabetes & metabolism in Pittsburgh
- Vijay BahlPittsburgh$998K
- Sachin BahlPittsburgh$162K
- Peter GrondziowskiPittsburgh$143K
- Patricia BononiPittsburgh$91K
- Murray GordonPittsburgh$60K
- Frederico ToledoPittsburgh$50K
- Hugo LinPittsburgh$21K
- Pouneh FazeliPittsburgh$20K
- Serge JabbourPhiladelphia$1.2M
- Geraldo SaavedraWhitehall$698K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.